Detalles de la búsqueda
1.
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
J Med Virol
; 93(6): 3985-3990, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33300183
2.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
AIDS Res Ther
; 16(1): 23, 2019 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31464642
3.
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
J Antimicrob Chemother
; 71(1): 244-50, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26483516
4.
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Ann Hepatol
; 15(4): 512-23, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236150
5.
Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
HIV Clin Trials
; 14(1): 45-50, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23372114
6.
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection.
HIV Res Clin Pract
; 21(2-3): 83-89, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32715952
7.
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
HIV Res Clin Pract
; 21(6): 151-167, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528318
8.
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 34(5): 707-718, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31833849
9.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
AIDS Res Hum Retroviruses
; 36(1): 48-57, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31516033
10.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Antiviral Res
; 170: 104543, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31279073
11.
Prevalence of Darunavir Resistance in the United States from 2010 to 2017.
AIDS Res Hum Retroviruses
; 34(12): 1036-1043, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30148406
12.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Lancet HIV
; 5(1): e23-e34, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28993180
13.
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 32(11): 1431-1442, 2018 07 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29683855
14.
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
HIV Clin Trials
; 18(5-6): 196-204, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29143565
15.
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.
AIDS Res Hum Retroviruses
; 31(6): 628-35, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25684627
16.
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial.
Pediatr Infect Dis J
; 34(5): e132-7, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25719453
17.
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
Antiviral Res
; 116: 10-6, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25614456
18.
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Pediatr Infect Dis J
; 33(9): 940-5, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25361024
19.
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis.
J Int AIDS Soc
; 17(4 Suppl 3): 19626, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25394130
20.
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Antivir Ther
; 18(3): 289-300, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23558157